ENLV - CIK 0001596812
The table below shows Enlivex Therapeutics Ltd.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$10.42M | -$13.01M | -$23.52M | -$23.95M | -$17.54M | -$11.01M |
| Capital expenditure | $68.00K | $103.00K | $236.00K | $8.12M | $1.63M | $1.02M |
| Investing cash flow | -$1.32M | $9.06M | -$25.97M | $62.52M | -$38.41M | -$20.98M |
| Dividends paid | - | - | - | - | - |
Enlivex Therapeutics Ltd. reported operating cash flow of -$10.42M for fiscal year 2025. That is up 19.9% from -$13.01M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$15.49M (FY 2016) to -$10.42M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $10.38M | $6.45M | $360.00K | $150.00K | $60.98M | $33.08M |